Completed NA INTERVENTIONAL 1-arm NCT00859833

Effects of Body Mass Index on the Hyperemic Response to Regadenoson

Sponsor: Astellas Pharma Inc

Conditions Decreased Vascular Flow Endothelial Dysfunction Obesity

Updated 9 times since 2017 Last updated: May 20, 2011 Started: Feb 28, 2009 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Decreased Vascular Flow and Endothelial Dysfunction and is currently completed. Astellas Pharma Inc leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Dec 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
University of Utah

Data source: University of Utah

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Salt Lake City, United States